Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors
Ryan B Corcoran,Khanh T Do,Jeong E Kim,James M Cleary,Aparna R Parikh,Oladapo O Yeku,Niya Xiong,Colin D Weekes,Jennifer Veneris,Leanne G Ahronian,Gianluca Mauri,Jun Tian,Bryanna L Norden,Alexa G Michel,Emily E Van Seventer,Giulia Siravegna,Kyle Camphausen,Gary Chi,Isobel J Fetter,Joan S Brugge,Helen X Chen,Naoko Takebe,Richard T Penson,Dejan Juric,Keith T Flaherty,Ryan J Sullivan,Jeffrey W Clark,Rebecca S Heist,Ursula A Matulonis,Joyce F Liu,Geoffrey I Shapiro,Ryan B. Corcoran,Khanh T. Do,Jeong E. Kim,James M. Cleary,Aparna R. Parikh,Oladapo O. Yeku,Colin D. Weekes,Leanne G. Ahronian,Bryanna L. Norden,Alexa G. Michel,Emily E. Van Seventer,Isobel J. Fetter,Joan S. Brugge,Helen X. Chen,Richard T. Penson,Keith T. Flaherty,Ryan J. Sullivan,Jeffrey W. Clark,Rebecca S. Heist,Ursula A. Matulonis,Joyce F. Liu,Geoffrey I. Shapiro
DOI: https://doi.org/10.1158/1078-0432.ccr-23-3135
IF: 13.801
2024-03-09
Clinical Cancer Research
Abstract:Purpose: MEK inhibitors (MEKi) lack monotherapy efficacy in most RAS-mutant cancers. BCL-xL is an anti-apoptotic protein identified by a synthetic lethal shRNA screen as a key suppressor of apoptotic response to MEKi. Patients and Methods: We conducted a dose escalation study (NCT02079740) of the BCL-xL inhibitor navitoclax and MEKi trametinib in patients with RAS-mutant tumors with expansion cohorts for: pancreatic, gynecologic (GYN), non-small cell lung cancer (NSCLC), and other cancers harboring KRAS/NRAS mutations. Paired pre-treatment and day 15 tumor biopsies and serial cell-free (cf)DNA were analyzed. Results: 91 patients initiated treatment, 38 in dose escalation. 58% had 33 prior therapies. 15 patients (17%) had colorectal cancer (CRC), 19 (11%) pancreatic, 15 (167%) NSCLC, and 32 (35%) GYN cancers. The recommended phase 2 dose (RP2D) was established as trametinib 2mg daily days 1-14 and navitoclax 250mg daily days 1-28 of each cycle. Most common adverse events included diarrhea, thrombocytopenia, increased AST/ALT, and acneiform rash. At RP2D, 8/49 (16.3%) evaluable patients achieved partial response (PR). Disease-specific differences in efficacy were noted. In GYN patients at the RP2D, 7/21 (33.3%) achieved a PR and median duration of response 8.2 months. No PRs occurred in CRC, NSCLC, or pancreatic patients. MAPK pathway inhibition was observed in on-treatment tumor biopsies. Reductions in KRAS/NRAS mutation levels in cfDNA correlated with clinical benefit. Conclusions: Navitoclax in combination with trametinib was tolerable. Durable clinical responses were observed in patients with RAS-mutant GYN cancers, warranting further evaluation in this population.
oncology